Downie Lilian

Dr. Downie Lilian


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2017 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
DLDownie Lilian
Downie Lilian
JHJane L Halliday
Jane L Halliday
RBRachel A Burt
Rachel A Burt
SLSebastian Lunke
Sebastian Lunke
ELElly Lynch
Elly Lynch
DADavid Amor
David Amor
Introduction The aetiology of congenital hearing loss is heterogeneous, and in many infants a genetic cause is suspected. Parents face a diagnostic odyssey when searching for a cause of their infant’s hearing loss. Through the Melbourne Genomics Health Alliance, a prospective cohort of infants will be offered whole-exome sequencing (WES) with targeted analysis in conjunction with chromosome microarray to determine the genetic causes of congenital hearing loss. Parents will also be offered the opportunity to receive additional results from their infant’s WES. Methods Eligible infants will be identified through the Victorian Infant Hearing Screening Program and offered an appointment in a paediatrician-run clinic, a genetics assessment and enrolment in the Victorian Childhood Hearing Impairment Longitudinal Databank. If parents consent to WES, genes causing deafness will be analysed and they can choose to obtain additional findings. For the additional results component, a modified laboratory protocol has been designed for reporting of results in the absence of a relevant phenotype. Parents’ experience of being offered WES will be evaluated using surveys. Discussion This project will provide descriptive analysis of the genetic aetiology of congenital hearing loss in this cohort and may provide data on genotype–phenotype correlations. Additionally, choices regarding additional findings will be analysed. Participants will represent a diverse cross section of the population, increasing the ability to generalise results beyond the study group. Evaluation surveys will allow analysis of preferences around counselling, usefulness of a decision aid and adequacy of information provision.

29 June 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ETErin Tutty
Erin Tutty
DADavid J. Amor
David J. Amor
AJAnna Jarmolowicz
Anna Jarmolowicz
KPKate Paton
Kate Paton
DLDownie Lilian
Downie Lilian

8 March 2025 in Prenatal Diagnosis
Verified
Journal Article
Open access
DLDownie Lilian
Downie Lilian
SLSebastian Lunke
Sebastian Lunke
ZSZornitza Stark
Zornitza Stark

23 July 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
NKNathasha Kugenthiran
Nathasha Kugenthiran
ETErin Tutty
Erin Tutty
AKAnaita Kanga-Parabia
Anaita Kanga-Parabia
JCJade Caruana
Jade Caruana
KSKatrina Scarff
Katrina Scarff
SBStephanie Best
Stephanie Best
Interest in the potential of population-based genomic sequencing is growing. However, integrating a large-scale screening program into an already complex healthcare system is challenging. The implementation of gNBS needs a thorough understanding of the process. The purpose of this study is to investigate how gNBS can be integrated into the Australian health system and delivered at scale. Embedded within the BabyScreen+ study, we utilised a research design informed by process mapping and phenomenology. Fifty-one semi-structured interviews with parents ( n = 33), healthcare providers ( n = 15), and BabyScreen+ study team members ( n = 8) were conducted. Additionally, we analysed the operational team meeting minutes. A baseline process map, developed in consultation with team members, consisted of six stages: 1. Raising awareness of the screening program; 2. Offer; 3. Participant enrolment and consent; 4. Sample collection; 5. Testing; and 6. Result disclosure and management. We recorded changes made over the study period to inform the post-implementation process map. Most changes occurred at stages: 1. Raising awareness, 4. Sample collection and 5. Testing. Lastly, a process map to inform the scale up of screening, was developed. Four key aspects of the gNBS process needing modification are: (1) growing awareness of screening amongst the public and HCPs; (2) building flexibility and accessibility into the consent process; (3) developing automation capabilities and infrastructure for large-scale sequencing and analysis, and (4) dedicated referral processes for infants who receive high-chance results. These findings demonstrate key system-level considerations and provide a foundation for implementing genomic newborn screening at scale within existing healthcare systems.

26 March 2025 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
SDSamantha Dayman
Samantha Dayman
MGMelissa Graetz
Melissa Graetz
LHLisa Hui
Lisa Hui
DLDownie Lilian
Downie Lilian
Background: Genomics has improved etiological diagnosis for foetal structural anomalies. It is being increasingly utilised in prenatal investigation both in Australia and internationally. To date, literature reporting diagnostic yield according to indication has been available. There is limited literature around the challenges of implementation and other aspects of utility. Aims: We aimed to explore the experiences and perspectives of clinicians involved with the delivery of a state‐wide public prenatal exome sequencing (pES) service in Australia. Materials and Methods: This qualitative study was developed using a pragmatism framework. A multidisciplinary cohort of clinicians across all tertiary foetal medicine units in Victoria was interviewed. Inductive content analysis was used to understand the experiences, impact, and utility of pES. Results: Eight clinician interviews were analysed. The impact of pES on clinicians included: increased pressure, higher emotional toll, and balancing the benefits with resource limitations. PES was most useful when it provided prognostic information. The clinicians felt that pES had the most utility for patients when the result informed their decision about whether or not to continue a pregnancy. Clinicians acknowledged their ‘gatekeeper’ role and valued a collaborative, multidisciplinary approach. The main perceived harm for patients was the anxiety associated with waiting times for results. Conclusions: This study provides insights into the delivery of a publicly funded pES program. Our findings highlight the importance of the multidisciplinary team in the successful implementation of genomic technologies in reproductive health.

3 November 2025 in Prenatal Diagnosis
Verified
Journal Article
Closed access
GGGulvir Gill
Gulvir Gill
KOKelly O'DOnovan
Kelly O'DOnovan
DRDina Rubinfeld
Dina Rubinfeld
SMSimon Meagher
Simon Meagher
SGStacy Goergen
Stacy Goergen
DLDownie Lilian
Downie Lilian